Core Concept of NGS-SELEX Traditional SELEX uses a few rounds of selection and cloning/Sanger sequencing of a handful of clones. NGS-SELEX performs deep sequencing (millions to billions of reads) at every selection round. This allows you to: Track the entire evolution of the oligonucleotide pool in real-time. Identify enriched sequences and families early. Perform sophisticated bioinformatics analysis to find winners, not just rely on final round abundance. Dramatically reduce the number of selection rounds needed (often 3-6 rounds instead of 8-15). Standard Service Workflow A full-service provider would typically offer the following pipeline: 1. Project Design & Library Synthesis Consultation: Target properties (protein, small molecule, cell), desired aptamer properties (Kd, specificity, buffer conditions). Library Design: Standard (40-60 nt random region) or custom (doped libraries, modified nucleotides like 2'-F, 2'-OMe, SOMAmers). Primer & Library Synthesis: Providing the initial, highly diverse DNA or RNA library (10^14 - 10^15 unique sequences). 2. SELEX Selection Immobilization: Immobilizing the target (on beads, column, plate) or using solution-based techniques (capture-SELEX, toggle-SELEX). Counter-Selection: Including steps to remove binders to immobilization matrix or off-targets. Stringency Control: Increasing selection pressure over rounds (e.g., reduced target concentration, increased wash stringency). Amplification: Careful PCR (with optimization to minimize bias) to regenerate the pool for the next round. 3. NGS & Core Bioinformatics Sample Preparation: Preparing sequencing…
Toggle-SELEX is a sophisticated and powerful variant of the traditional SELEX process for aptamer development, specifically designed to generate aptamers that recognize multiple, closely related targets or a specific epitope common across different species/conditions. Let's break down what an Aptamer Screening Service using Toggle-SELEX entails, its applications, and what you should consider when selecting a service provider. What is Toggle-SELEX? The core idea of Toggle-SELEX is to "toggle" or alternate the selection pressure between two (or more) related target molecules during the SELEX rounds. Traditional SELEX: Uses a single target to evolve aptamers with high affinity for that specific target. It often negatively selects against related molecules (counter-selection) to ensure specificity. Toggle-SELEX: Actively uses two positive selection targets in an alternating pattern. For example: Round 1: Select against Target A (e.g., human protein). Round 2: Select against Target B (e.g., mouse ortholog of the same protein). Round 3: Back to Target A, and so on. Counter-selection against unrelated structures is still used to maintain general specificity. This process enriches for nucleic acid sequences that bind to a conserved structural epitope present on both targets, while sequences that bind to unique epitopes on only one target are filtered out. Key Applications of Toggle-SELEX This method is invaluable when you need cross-reactive or broad-spectrum recognition: Cross-Species Reactive Aptamers: Develop aptamers for preclinical research. For example, an…
What is CE-SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is the standard process for aptamer development. It involves iterative rounds of selection and amplification to enrich nucleic acid sequences that bind tightly to a target molecule. Traditional SELEX often uses immobilization of the target on beads or filters, which can be slow (8-15 rounds) and may introduce bias by selecting for sequences that bind to the immobilization matrix itself. CE-SELEX uses Capillary Electrophoresis as the separation mechanism. The key principle is that when an aptamer binds to its target, it forms a complex with a different charge-to-size ratio, causing it to migrate at a different time (shifted peak) in the capillary compared to the unbound nucleic acid library. This complex can be isolated and collected with exquisite precision. Core Advantages of a CE-SELEX Screening Service A service provider offering CE-SELEX delivers significant benefits: Extreme Speed and Efficiency: Often requires only 2-4 rounds of selection to obtain high-affinity aptamers (nanomolar to picomolar Kd), compared to many more rounds in traditional SELEX. This translates to weeks or months of time saved. Solution-Phase Selection: The target is free in solution, eliminating immobilization bias. This allows for selection against targets in their native conformation and enables selection for small molecules and…
Aptamers are single-stranded oligonucleotides that fold into defined architectures and bind to targets such as proteins. In binding proteins they often inhibit protein–protein interactions and thereby may elicit therapeutic effects such as antagonism. Aptamers are discovered using SELEX (systematic evolution of ligands by exponential enrichment), a directed in vitro evolution technique in which large libraries of degenerate oligonucleotides are iteratively and alternately partitioned for target binding. They are then amplified enzymatically until functional sequences are identified by the sequencing of cloned individuals. For most therapeutic purposes, aptamers are truncated to reduce synthesis costs, modified at the sugars and capped at their termini to increase nuclease resistance, and conjugated to polyethylene glycol or another entity to reduce renal filtration rates. The first aptamer approved for a therapeutic application was pegaptanib sodium (Macugen; Pfizer/Eyetech), which was approved in 2004 by the US Food and Drug Administration for macular degeneration. Eight other aptamers are currently undergoing clinical evaluation for various haematology, oncology, ocular and inflammatory indications. Aptamers are ultimately chemically synthesized in a readily scalable process in which specific conjugation points are introduced with defined stereochemistry. Unlike some protein therapeutics, aptamers do not elicit antibodies, and because aptamers generally contain sugars modified at their 2′-positions,…
What is an Aptamer? An aptamer is a short, single-stranded oligonucleotide (DNA or RNA) or peptide that binds to a specific target molecule (e.g., proteins, small molecules, cells, viruses) with high affinity and specificity. Often called "chemical antibodies," they offer advantages like stability, low-cost synthesis, and minimal batch-to-batch variation. The Core Process: SELEX The standard method for aptamer selection is SELEX (Systematic Evolution of Ligands by EXponential enrichment). Basic SELEX Workflow: Library Synthesis: Create a vast random-sequence oligonucleotide library (typically 10¹³ - 10¹⁵ unique sequences) flanked by constant primer regions for PCR amplification. Incubation: The library is incubated with the target molecule under controlled conditions (buffer, temperature, time). Partitioning: Bound sequences are separated from unbound ones. This is the most critical step and varies based on target (e.g., filtration, affinity columns, magnetic bead separation). Elution: Bound aptamers are recovered from the target (e.g., by denaturation or competitive elution). Amplification: The recovered pool is amplified by PCR (for DNA) or RT-PCR (for RNA) to create an enriched library for the next round. Iteration: Steps 2-5 are repeated (typically 8-15 rounds) to progressively enrich for sequences with the highest affinity and specificity. Cloning & Sequencing: The final enriched pool is cloned and sequenced to identify individual aptamer candidates. Key Variants of…
“Aptamer fields” can be understood as the interconnected research and application areas where aptamers—short, single-stranded DNA or RNA molecules—are designed and used as highly selective binding agents (often described as “chemical antibodies”) for targets ranging from proteins and small molecules to whole cells. This article explains what defines the aptamer fields, how aptamers are created, where they’re used, and what technical trends are shaping the space. 1) What Are Aptamers (and Why They Matter in Aptamer Fields)? Aptamers are typically ~20–100 nucleotides long and fold into 3D structures that bind specific targets with high affinity and specificity. Unlike antibodies (biological proteins), aptamers are nucleic acids, which affects how they are discovered, synthesized, modified, and integrated into devices. Key reasons aptamers have become a “field” rather than a niche tool: Programmability: sequence-controlled design and chemical modification Manufacturability: scalable synthesis routes compared with biological production Versatility: diagnostics, biosensing, therapeutics, imaging, and research reagents 2) The Core Engine: SELEX and How Aptamers Are Discovered Most aptamers are generated using SELEX (Systematic Evolution of Ligands by EXponential enrichment), an iterative in-vitro selection process that enriches sequences that bind a chosen target. In common workflows, a large random library is…
Aptamers are short, single-stranded DNA or RNA sequences that fold into 3D shapes capable of binding specific targets—proteins, small molecules, ions, cells, or even complex mixtures—with high affinity and selectivity. Because they are chemically synthesized, readily modified, and often less immunogenic than protein binders, aptamers have matured into a versatile “molecular toolkit” used across diagnostics, biosensing, therapeutics, imaging, and bioprocessing. This article explains APTAMER APPLICATIONS from fundamentals to advanced use-cases, with an emphasis on how teams translate an aptamer sequence into a functioning assay, sensor, drug carrier, or imaging probe. 1) How Aptamers Are Created (Why Selection Method Shapes Applications) Most aptamers are discovered through SELEX (Systematic Evolution of Ligands by EXponential enrichment): iterative rounds of binding, separation, and amplification that enrich sequences best suited to a chosen target and conditions. Modern SELEX variants—such as cell-SELEX, microfluidic SELEX, and capillary electrophoresis SELEX—aim to shorten selection time, improve specificity, and better match real-world sample environments. The practical result is that application performance often depends as much on selection constraints (buffer, temperature, counter-selection targets, matrix effects) as on the final nucleotide sequence. Key takeaway: If the intended application involves serum, saliva, food extracts, or environmental water, designing SELEX conditions to…
Aptamers are short, single-stranded nucleic acid molecules (DNA or RNA) that fold into specific 3D shapes and bind targets with high affinity and selectivity—often compared to how antibodies recognize antigens, but built from nucleic acids rather than proteins. Unlike a “generic DNA strand,” an aptamer’s function comes from structure: loops, stems, bulges, pseudoknots, and other motifs that create a binding surface matching a target’s geometry and chemistry. Targets can include proteins, peptides, small molecules, ions, and even whole cells (depending on the selection strategy). Why Aptamers Matter (and How They Differ From Antibodies) Aptamers are often described as “chemical antibodies,” but the differences are exactly why they’re valuable. Key advantages frequently highlighted Low immunogenicity (reduced risk of provoking immune responses) High stability and the ability to refold after denaturation in many cases Easy chemical synthesis (batch consistency, scalable manufacturing) Straightforward modification (labels, linkers, immobilization handles) Trade-offs you should know Nuclease sensitivity (especially RNA aptamers) can be a limitation in biological fluids unless stabilized. Selection bias can occur during discovery (e.g., PCR bias), meaning “best in the tube” isn’t always “best in reality.” Very high affinity does not automatically guarantee best real-world specificity; selection conditions matter. …
